Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- John Mascarenhas, MD
Icahn School of Medicine at Mount Sinai
Study Chair - Michal Bar-Natan, MD
Icahn School of Medicine at Mount Sinai
Principal Investigator - Ronald Hoffman, MD
Icahn School of Medicine at Mount Sinai
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
11 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Princess Margaret Cancer Centre
Toronto, Canada
- Mayo Clinic - Arizona
Scottsdale, Arizona, United States
- Cedars-Sinai Medical Center
Los Angeles, California, United States
- Moffitt Cancer Center
Tampa, Florida, United States
- University of Kansas Cancer Center
Westwood, Kansas, United States
- University of Michigan Rogel Cancer Center
Ann Arbor, Michigan, United States
- Icahn School of Medicine at Mount Sinai
New York, New York, United States
- Memorial Sloan-Kettering Cancer Center
New York, New York, United States
- Wake Forest Baptist Health
Winston-Salem, North Carolina, United States
- Taussig Cancer Center Institute
Cleveland, Ohio, United States
- Mays Cancer Center at Ut Health San Antonio
San Antonio, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 14 Jan 2021
- Primary completion
- 30 May 2023
- Completion
- 30 May 2023
- Last update posted
- 4 Feb 2025
- Registered enrollment
- 6
- Registry id
- NCT04281498
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.